Skip to main content
Top

2018 | OriginalPaper | Chapter

11. BRDT Inhibitors for Male Contraceptive Drug Discovery: Current Status

Authors : Zhenyuan Miao, Xianghong Guan, Jiewei Jiang, Gunda I. Georg

Published in: Targeting Protein-Protein Interactions by Small Molecules

Publisher: Springer Singapore

Activate our intelligent search to find suitable subject content or patents.

search-config
loading …

Abstract

As epigenetic readers, the bromodomain and extra-terminal domain (BET) protein family binds to acetyl-lysine (KAc) residues and regulates chromatin structure and gene expression. Inhibition of BET proteins by small-molecule inhibitors for a variety of therapeutic applications has garnered increasing interest, as many compounds have advanced into human clinical trials for various diseases. The BET bromodomain family is composed of BRD2, BRD3, BRD4, and testis-specific BRDT. Knockout studies in mice have validated Brdt-1 as a potential target for male non-hormonal contraception, and the pan-BET inhibitor JQ1 was identified as an effective and reversible contraceptive. Numerous small-molecule compounds with potent inhibitory activity against BET family proteins have been reported. However, most of these inhibitors show minimal intra-BET selectivity due to high levels of sequence homology among the BET subfamily members and shared common structural architecture. Therefore, the discovery of selective small-molecule inhibitors against BRDT for male contraception remains a challenge for the future. This review will cover the structure and function of BRDT, known BRDT inhibitors and discuss potential approaches to discover selective BRDT inhibitors.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Literature
1.
go back to reference Filippakopoulos P, Knapp S (2014) Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13(5):337–356CrossRefPubMed Filippakopoulos P, Knapp S (2014) Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13(5):337–356CrossRefPubMed
2.
go back to reference Prinjha RK, Witherington J, Lee K (2012) Place your BETs: the therapeutic potential of bromodomains. Trends Pharmacol Sci 33(3):146–153CrossRefPubMed Prinjha RK, Witherington J, Lee K (2012) Place your BETs: the therapeutic potential of bromodomains. Trends Pharmacol Sci 33(3):146–153CrossRefPubMed
4.
go back to reference Bennett RL, Licht JD (2018) Targeting epigenetics in cancer. Annu Rev Pharmacol Toxicol 58(1):187–207CrossRefPubMed Bennett RL, Licht JD (2018) Targeting epigenetics in cancer. Annu Rev Pharmacol Toxicol 58(1):187–207CrossRefPubMed
5.
go back to reference Verdin E, Ott M (2014) 50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond. Nat Rev Mol Cell Biol 16:258CrossRefPubMed Verdin E, Ott M (2014) 50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond. Nat Rev Mol Cell Biol 16:258CrossRefPubMed
7.
go back to reference Scanlan MJ, Altorki NK, Gure AO, Williamson B, Jungbluth A, Chen Y-T, Old LJ (2000) Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett 150(2):155–164CrossRefPubMed Scanlan MJ, Altorki NK, Gure AO, Williamson B, Jungbluth A, Chen Y-T, Old LJ (2000) Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett 150(2):155–164CrossRefPubMed
8.
go back to reference Pérez-Salvia M, Esteller M (2017) Bromodomain inhibitors and cancer therapy: From structures to applications. Epigenetics 12(5):323–339CrossRefPubMed Pérez-Salvia M, Esteller M (2017) Bromodomain inhibitors and cancer therapy: From structures to applications. Epigenetics 12(5):323–339CrossRefPubMed
9.
go back to reference Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, Lemieux ME, Picaud S, Yu RN, Qi J, Knapp S, Bradner JE (2012) Small-molecule inhibition of BRDT for male contraception. Cell 150(4):673–684CrossRefPubMedPubMedCentral Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, Lemieux ME, Picaud S, Yu RN, Qi J, Knapp S, Bradner JE (2012) Small-molecule inhibition of BRDT for male contraception. Cell 150(4):673–684CrossRefPubMedPubMedCentral
10.
go back to reference Shang E, Nickerson HD, Wen D, Wang X, Wolgemuth DJ (2007) The first bromodomain of Brdt, a testis-specific member of the BET sub-family of double-bromodomain-containing proteins, is essential for male germ cell differentiation. Development 134(19):3507–3715CrossRefPubMed Shang E, Nickerson HD, Wen D, Wang X, Wolgemuth DJ (2007) The first bromodomain of Brdt, a testis-specific member of the BET sub-family of double-bromodomain-containing proteins, is essential for male germ cell differentiation. Development 134(19):3507–3715CrossRefPubMed
11.
go back to reference Barda S, Yogev L, Paz G, Yavetz H, Lehavi O, Hauser R, Doniger T, Breitbart H, Kleiman SE (2014) BRDT gene sequence in human testicular pathologies and the implication of its single nucleotide polymorphism (rs3088232) on fertility. Andrology 2:641–647CrossRefPubMed Barda S, Yogev L, Paz G, Yavetz H, Lehavi O, Hauser R, Doniger T, Breitbart H, Kleiman SE (2014) BRDT gene sequence in human testicular pathologies and the implication of its single nucleotide polymorphism (rs3088232) on fertility. Andrology 2:641–647CrossRefPubMed
12.
go back to reference Filippakopoulos P, Knapp S (2014) Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13:337–356CrossRefPubMed Filippakopoulos P, Knapp S (2014) Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13:337–356CrossRefPubMed
13.
go back to reference Hewings DS, Rooney TPC, Jennings LE, Hay DA, Schofield CJ, Brennan PE, Knapp S, Conway SJ (2012) Progress in the development and application of small molecule inhibitors of bromodomain–acetyl-lysine interactions. J Med Chem 55(22):9393–9413CrossRefPubMed Hewings DS, Rooney TPC, Jennings LE, Hay DA, Schofield CJ, Brennan PE, Knapp S, Conway SJ (2012) Progress in the development and application of small molecule inhibitors of bromodomain–acetyl-lysine interactions. J Med Chem 55(22):9393–9413CrossRefPubMed
14.
go back to reference Chun-wa C, Jason W (2011) Progress in the discovery of small-molecule inhibitors of bromodomain–histone interactions. J Biomol Screen 16(10):1170–1185CrossRef Chun-wa C, Jason W (2011) Progress in the discovery of small-molecule inhibitors of bromodomain–histone interactions. J Biomol Screen 16(10):1170–1185CrossRef
15.
go back to reference Arntson KE, Pomerantz WCK (2016) Protein-observed fluorine NMR: a bioorthogonal approach for small molecule discovery. J Med Chem 59(11):5158–5171CrossRefPubMed Arntson KE, Pomerantz WCK (2016) Protein-observed fluorine NMR: a bioorthogonal approach for small molecule discovery. J Med Chem 59(11):5158–5171CrossRefPubMed
16.
go back to reference Zhang G, Smith SG, Zhou M-M (2015) Discovery of chemical inhibitors of human bromodomains. Chem Rev 115(21):11625–11668CrossRefPubMed Zhang G, Smith SG, Zhou M-M (2015) Discovery of chemical inhibitors of human bromodomains. Chem Rev 115(21):11625–11668CrossRefPubMed
17.
go back to reference Romero FA, Taylor AM, Crawford TD, Tsui V, Cote A, Magnuson S (2016) Disrupting acetyl-lysine recognition: progress in the development of bromodomain inhibitors. J Med Chem 59(4):1271–1298CrossRefPubMed Romero FA, Taylor AM, Crawford TD, Tsui V, Cote A, Magnuson S (2016) Disrupting acetyl-lysine recognition: progress in the development of bromodomain inhibitors. J Med Chem 59(4):1271–1298CrossRefPubMed
18.
go back to reference Liu Z, Wang P, Chen H, Wold EA, Tian B, Brasier AR, Zhou J (2017) Drug discovery targeting bromodomain-containing protein 4. J Med Chem 60(11):4533–4558CrossRefPubMedPubMedCentral Liu Z, Wang P, Chen H, Wold EA, Tian B, Brasier AR, Zhou J (2017) Drug discovery targeting bromodomain-containing protein 4. J Med Chem 60(11):4533–4558CrossRefPubMedPubMedCentral
19.
go back to reference Smith SG, Zhou M-M (2016) The bromodomain: a new target in emerging epigenetic medicine. ACS Chem Biol 11(3):598–608CrossRefPubMed Smith SG, Zhou M-M (2016) The bromodomain: a new target in emerging epigenetic medicine. ACS Chem Biol 11(3):598–608CrossRefPubMed
20.
go back to reference Gallenkamp D, Gelato KA, Haendler B, Weinmann H (2014) Bromodomains and their pharmacological inhibitors. ChemMedChem 9(3):438–464CrossRefPubMed Gallenkamp D, Gelato KA, Haendler B, Weinmann H (2014) Bromodomains and their pharmacological inhibitors. ChemMedChem 9(3):438–464CrossRefPubMed
21.
go back to reference C-w Chung, Coste H, White JH, Mirguet O, Wilde J, Gosmini RL, Delves C, Magny SM, Woodward R, Hughes SA, Boursier EV, Flynn H, Bouillot AM, Bamborough P, Brusq J-MG, Gellibert FJ, Jones EJ, Riou AM, Homes P, Martin SL, Uings IJ, Toum J, Clément CA, Boullay A-B, Grimley RL, Blandel FM, Prinjha RK, Lee K, Kirilovsky J, Nicodeme E (2011) Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem 54(11):3827–3838CrossRef C-w Chung, Coste H, White JH, Mirguet O, Wilde J, Gosmini RL, Delves C, Magny SM, Woodward R, Hughes SA, Boursier EV, Flynn H, Bouillot AM, Bamborough P, Brusq J-MG, Gellibert FJ, Jones EJ, Riou AM, Homes P, Martin SL, Uings IJ, Toum J, Clément CA, Boullay A-B, Grimley RL, Blandel FM, Prinjha RK, Lee K, Kirilovsky J, Nicodeme E (2011) Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem 54(11):3827–3838CrossRef
22.
go back to reference McDaniel KF, Wang L, Soltwedel T, Fidanze SD, Hasvold LA, Liu D, Mantei RA, Pratt JK, Sheppard GS, Bui MH, Faivre EJ, Huang X, Li L, Lin X, Wang R, Warder SE, Wilcox D, Albert DH, Magoc TJ, Rajaraman G, Park CH, Hutchins CW, Shen JJ, Edalji RP, Sun CC, Martin R, Gao W, Wong S, Fang G, Elmore SW, Shen Y, Kati WM (2017) Discovery of N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a potent and orally available bromodomain and extraterminal domain (BET) family bromodomain inhibitor. J Med Chem 60(20):8369–8384CrossRefPubMed McDaniel KF, Wang L, Soltwedel T, Fidanze SD, Hasvold LA, Liu D, Mantei RA, Pratt JK, Sheppard GS, Bui MH, Faivre EJ, Huang X, Li L, Lin X, Wang R, Warder SE, Wilcox D, Albert DH, Magoc TJ, Rajaraman G, Park CH, Hutchins CW, Shen JJ, Edalji RP, Sun CC, Martin R, Gao W, Wong S, Fang G, Elmore SW, Shen Y, Kati WM (2017) Discovery of N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a potent and orally available bromodomain and extraterminal domain (BET) family bromodomain inhibitor. J Med Chem 60(20):8369–8384CrossRefPubMed
23.
go back to reference Theodoulou NH, Tomkinson CO, Prinjha RK, Humphreys PG (2016) Clinical progress and pharmacology of small molecule bromodomain inhibitors. Curr Opin Chem Biol 33:58–66CrossRefPubMed Theodoulou NH, Tomkinson CO, Prinjha RK, Humphreys PG (2016) Clinical progress and pharmacology of small molecule bromodomain inhibitors. Curr Opin Chem Biol 33:58–66CrossRefPubMed
24.
go back to reference Noel JK, Iwata K, Ooike S, Sugahara K, Nakamura H, Daibata M (2013) Abstract C244: development of the BET bromodomain inhibitor OTX015. Mol Cancer Ther 12(11 Supplement):C244CrossRef Noel JK, Iwata K, Ooike S, Sugahara K, Nakamura H, Daibata M (2013) Abstract C244: development of the BET bromodomain inhibitor OTX015. Mol Cancer Ther 12(11 Supplement):C244CrossRef
25.
go back to reference Coudé M-M, Braun T, Berrou J, Mélanie Dupont1, Bertrand S, Masse A, Raffoux E, Itzykson R, Delord M, Riveiro ME, Herait P, Baruchel A, Dombret H, Gardin C (2015) Progress in the discovery of small-molecule inhibitors of bromodomain–histone interactions. Oncotarget 6:17698–17712 Coudé M-M, Braun T, Berrou J, Mélanie Dupont1, Bertrand S, Masse A, Raffoux E, Itzykson R, Delord M, Riveiro ME, Herait P, Baruchel A, Dombret H, Gardin C (2015) Progress in the discovery of small-molecule inhibitors of bromodomain–histone interactions. Oncotarget 6:17698–17712
26.
go back to reference Picaud S, Wells C, Felletar I, Brotherton D, Martin S, Savitsky P, Diez-Dacal B, Philpott M, Bountra C, Lingard H, Fedorov O, Müller S, Brennan PE, Knapp S, Filippakopoulos P (2013) RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci USA 110(49):19754–19759CrossRefPubMed Picaud S, Wells C, Felletar I, Brotherton D, Martin S, Savitsky P, Diez-Dacal B, Philpott M, Bountra C, Lingard H, Fedorov O, Müller S, Brennan PE, Knapp S, Filippakopoulos P (2013) RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci USA 110(49):19754–19759CrossRefPubMed
27.
go back to reference Gilham D, Wasiak S, Tsujikawa LM, Halliday C, Norek K, Patel RG, Kulikowski E, Johansson J, Sweeney M, Wong NCW (2016) RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease. Atherosclerosis 247:48–57CrossRefPubMed Gilham D, Wasiak S, Tsujikawa LM, Halliday C, Norek K, Patel RG, Kulikowski E, Johansson J, Sweeney M, Wong NCW (2016) RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease. Atherosclerosis 247:48–57CrossRefPubMed
28.
go back to reference Nicholls SJ, Gordon A, Johannson J, Ballantyne CM, Barter PJ, Brewer HB, Kastelein JJP, Wong NC, Borgman MRN, Nissen SE (2012) ApoA-I induction as a potential cardioprotective strategy: Rationale for the SUSTAIN and ASSURE studies. Cardiovasc Drugs Ther 26(2):181–187CrossRefPubMed Nicholls SJ, Gordon A, Johannson J, Ballantyne CM, Barter PJ, Brewer HB, Kastelein JJP, Wong NC, Borgman MRN, Nissen SE (2012) ApoA-I induction as a potential cardioprotective strategy: Rationale for the SUSTAIN and ASSURE studies. Cardiovasc Drugs Ther 26(2):181–187CrossRefPubMed
29.
go back to reference Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Muller S, Pawson T, Gingras AC, Arrowsmith CH, Knapp S (2012) Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149(1):214–231CrossRefPubMedPubMedCentral Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Muller S, Pawson T, Gingras AC, Arrowsmith CH, Knapp S (2012) Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149(1):214–231CrossRefPubMedPubMedCentral
32.
go back to reference Miller TCR, Simon B, Rybin V, Grötsch H, Curtet S, Khochbin S, Carlomagno T, Müller CW (2016) A bromodomain–DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT. Nat Commun 7:13855CrossRefPubMedPubMedCentral Miller TCR, Simon B, Rybin V, Grötsch H, Curtet S, Khochbin S, Carlomagno T, Müller CW (2016) A bromodomain–DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT. Nat Commun 7:13855CrossRefPubMedPubMedCentral
33.
go back to reference Moriniere J, Rousseaux S, Steuerwald U, Soler-Lopez M, Curtet S, Vitte AL, Govin J, Gaucher J, Sadoul K, Hart DJ, Krijgsveld J, Khochbin S, Muller CW, Petosa C (2009) Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 461(7264):664–668CrossRefPubMed Moriniere J, Rousseaux S, Steuerwald U, Soler-Lopez M, Curtet S, Vitte AL, Govin J, Gaucher J, Sadoul K, Hart DJ, Krijgsveld J, Khochbin S, Muller CW, Petosa C (2009) Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 461(7264):664–668CrossRefPubMed
34.
go back to reference Martin MP, Olesen SH, Georg GI, Schonbrunn E (2013) Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem Biol 8(11):2360–2365CrossRefPubMed Martin MP, Olesen SH, Georg GI, Schonbrunn E (2013) Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem Biol 8(11):2360–2365CrossRefPubMed
35.
go back to reference Berkovits BD, Wolgemuth DJ (2013) The role of the double bromodomain-containing BET genes during mammalian spermatogenesis. Curr Top Dev Biol 102:293–326CrossRefPubMedPubMedCentral Berkovits BD, Wolgemuth DJ (2013) The role of the double bromodomain-containing BET genes during mammalian spermatogenesis. Curr Top Dev Biol 102:293–326CrossRefPubMedPubMedCentral
36.
go back to reference Gaucher J, Boussouar F, Montellier E, Curtet S, Buchou T, Bertrand S, Hery P, Jounier S, Depaux A, Vitte AL, Guardiola P, Pernet K, Debernardi A, Lopez F, Holota H, Imbert J, Wolgemuth DJ, Gerard M, Rousseaux S, Khochbin S (2012) Bromodomain-dependent stage-specific male genome programming by Brdt. EMBO J 31(19):3809–3820CrossRefPubMedPubMedCentral Gaucher J, Boussouar F, Montellier E, Curtet S, Buchou T, Bertrand S, Hery P, Jounier S, Depaux A, Vitte AL, Guardiola P, Pernet K, Debernardi A, Lopez F, Holota H, Imbert J, Wolgemuth DJ, Gerard M, Rousseaux S, Khochbin S (2012) Bromodomain-dependent stage-specific male genome programming by Brdt. EMBO J 31(19):3809–3820CrossRefPubMedPubMedCentral
37.
go back to reference Barda S, Yogev L, Paz G, Yavetz H, Hauser R, Breitbart H, Kleiman SE (2016) New insights into the role of the Brdt protein in the regulation of development and spermatogenesis in the mouse. Gene Expr Patterns 20(2):130–137CrossRefPubMed Barda S, Yogev L, Paz G, Yavetz H, Hauser R, Breitbart H, Kleiman SE (2016) New insights into the role of the Brdt protein in the regulation of development and spermatogenesis in the mouse. Gene Expr Patterns 20(2):130–137CrossRefPubMed
38.
go back to reference Barda S, Paz G, Yogev L, Yavetz H, Lehavi O, Hauser R, Botchan A, Breitbart H, Kleiman SE (2012) Expression of BET genes in testis of men with different spermatogenic impairments. Fertil Steril 97 (1):46–52.e45CrossRefPubMed Barda S, Paz G, Yogev L, Yavetz H, Lehavi O, Hauser R, Botchan A, Breitbart H, Kleiman SE (2012) Expression of BET genes in testis of men with different spermatogenic impairments. Fertil Steril 97 (1):46–52.e45CrossRefPubMed
39.
go back to reference Berkovits BD, Wang L, Guarnieri P, Wolgemuth DJ (2012) The testis-specific double bromodomain-containing protein BRDT forms a complex with multiple spliceosome components and is required for mRNA splicing and 3′-UTR truncation in round spermatids. Nucleic Acids Res 40(15):7162–7175CrossRefPubMedPubMedCentral Berkovits BD, Wang L, Guarnieri P, Wolgemuth DJ (2012) The testis-specific double bromodomain-containing protein BRDT forms a complex with multiple spliceosome components and is required for mRNA splicing and 3′-UTR truncation in round spermatids. Nucleic Acids Res 40(15):7162–7175CrossRefPubMedPubMedCentral
40.
go back to reference Wang L, Wolgemuth DJ (2016) BET protein BRDT complexes with HDAC1, PRMT5, and TRIM28 and functions in transcriptional repression during spermatogenesis. J Cell Biochem 117(6):1429–1438CrossRefPubMed Wang L, Wolgemuth DJ (2016) BET protein BRDT complexes with HDAC1, PRMT5, and TRIM28 and functions in transcriptional repression during spermatogenesis. J Cell Biochem 117(6):1429–1438CrossRefPubMed
42.
go back to reference Kogan P, Wald M (2014) Male contraception: history and development. Urol Clin North Am 41(1):145–161CrossRefPubMed Kogan P, Wald M (2014) Male contraception: history and development. Urol Clin North Am 41(1):145–161CrossRefPubMed
44.
go back to reference Heinemann K, Saad F, Wiesemes M, White S, Heinemann L (2005) Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod 20(2):549–556CrossRefPubMed Heinemann K, Saad F, Wiesemes M, White S, Heinemann L (2005) Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod 20(2):549–556CrossRefPubMed
46.
go back to reference Murdoch FE, Goldberg E (2014) Male contraception: Another holy grail. Bioorg Med Chem Lett 24(2):419–424CrossRefPubMed Murdoch FE, Goldberg E (2014) Male contraception: Another holy grail. Bioorg Med Chem Lett 24(2):419–424CrossRefPubMed
47.
go back to reference Zdrojewicz Z, Konieczny R, Papier P (2015) Brdt bromodomain Inhibitors and other modern means of male contraception. Adv Clin Exp Med 24:705–714CrossRefPubMed Zdrojewicz Z, Konieczny R, Papier P (2015) Brdt bromodomain Inhibitors and other modern means of male contraception. Adv Clin Exp Med 24:705–714CrossRefPubMed
48.
go back to reference Lee DU, Katavolos P, Palanisamy G, Katewa A, Sioson C, Corpuz J, Pang J, DeMent K, Choo E, Ghilardi N, Diaz D, Danilenko DM (2016) Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice. Toxicol Appl Pharmacol 300:47–54CrossRefPubMed Lee DU, Katavolos P, Palanisamy G, Katewa A, Sioson C, Corpuz J, Pang J, DeMent K, Choo E, Ghilardi N, Diaz D, Danilenko DM (2016) Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice. Toxicol Appl Pharmacol 300:47–54CrossRefPubMed
49.
go back to reference Korb E, Herre M, Zucker-Scharff I, Darnell RB, Allis CD (2015) BET protein Brd4 activates transcription in neurons and BET inhibitor JQ1 blocks memory in mice. Nat Neurosci 18(10):1464–1473CrossRefPubMedPubMedCentral Korb E, Herre M, Zucker-Scharff I, Darnell RB, Allis CD (2015) BET protein Brd4 activates transcription in neurons and BET inhibitor JQ1 blocks memory in mice. Nat Neurosci 18(10):1464–1473CrossRefPubMedPubMedCentral
50.
go back to reference Brand M, Measures AM, Wilson BG, Cortopassi WA, Alexander R, Höss M, Hewings DS, Rooney TPC, Paton RS, Conway SJ (2015) Small molecule inhibitors of bromodomain–acetyl-lysine interactions. ACS Chem Biol 10(1):22–39CrossRefPubMed Brand M, Measures AM, Wilson BG, Cortopassi WA, Alexander R, Höss M, Hewings DS, Rooney TPC, Paton RS, Conway SJ (2015) Small molecule inhibitors of bromodomain–acetyl-lysine interactions. ACS Chem Biol 10(1):22–39CrossRefPubMed
51.
go back to reference Ran X, Zhao Y, Liu L, Bai L, Yang C-Y, Zhou B, Meagher JL, Chinnaswamy K, Stuckey JA, Wang S (2015) Structure-based design of γ-carboline analogues as potent and specific bet bromodomain inhibitors. J Med Chem 58(12):4927–4939CrossRefPubMedPubMedCentral Ran X, Zhao Y, Liu L, Bai L, Yang C-Y, Zhou B, Meagher JL, Chinnaswamy K, Stuckey JA, Wang S (2015) Structure-based design of γ-carboline analogues as potent and specific bet bromodomain inhibitors. J Med Chem 58(12):4927–4939CrossRefPubMedPubMedCentral
52.
go back to reference Sasaki K, Ito A, Yoshida M (2012) Development of live-cell imaging probes for monitoring histone modifications. Bioorg Med Chem 20(6):1887–1892CrossRefPubMed Sasaki K, Ito A, Yoshida M (2012) Development of live-cell imaging probes for monitoring histone modifications. Bioorg Med Chem 20(6):1887–1892CrossRefPubMed
53.
go back to reference Tanaka M, Roberts JM, Seo HS, Souza A, Paulk J, Scott TG, DeAngelo SL, Dhe-Paganon S, Bradner JE (2016) Design and characterization of bivalent BET inhibitors. Nat Chem Biol 12(12):1089–1096CrossRefPubMedPubMedCentral Tanaka M, Roberts JM, Seo HS, Souza A, Paulk J, Scott TG, DeAngelo SL, Dhe-Paganon S, Bradner JE (2016) Design and characterization of bivalent BET inhibitors. Nat Chem Biol 12(12):1089–1096CrossRefPubMedPubMedCentral
54.
55.
go back to reference Bryant J, Donahue G, Wang X, Meyer-Ficca M, Luense L, Weller A, Bartolomei M, Blobel G, Meyer R, Garcia B, Berger S (2015) Characterization of BRD4 during mammalian postmeiotic sperm development. Mol Cell Biol 35:1433–1448CrossRefPubMedPubMedCentral Bryant J, Donahue G, Wang X, Meyer-Ficca M, Luense L, Weller A, Bartolomei M, Blobel G, Meyer R, Garcia B, Berger S (2015) Characterization of BRD4 during mammalian postmeiotic sperm development. Mol Cell Biol 35:1433–1448CrossRefPubMedPubMedCentral
56.
go back to reference Raux B, Voitovich Y, Derviaux C, Lugari A, Rebuffet E, Milhas S, Priet S, Roux T, Trinquet E, Guillemot JC, Knapp S, Brunel JM, Fedorov AY, Collette Y, Roche P, Betzi S, Combes S, Morelli X (2016) Exploring selective inhibition of the first bromodomain of the human bromodomain and extra-terminal domain (BET) proteins. J Med Chem 59(4):1634–1641CrossRefPubMed Raux B, Voitovich Y, Derviaux C, Lugari A, Rebuffet E, Milhas S, Priet S, Roux T, Trinquet E, Guillemot JC, Knapp S, Brunel JM, Fedorov AY, Collette Y, Roche P, Betzi S, Combes S, Morelli X (2016) Exploring selective inhibition of the first bromodomain of the human bromodomain and extra-terminal domain (BET) proteins. J Med Chem 59(4):1634–1641CrossRefPubMed
57.
go back to reference Ouyang L, Zhang L, Liu J, Fu L, Yao D, Zhao Y, Zhang S, Wang G, He G, Liu B (2017) Discovery of a small-molecule bromodomain-containing protein 4 (BRD4) Inhibitor that induces AMP-activated protein kinase-modulated autophagy-associated cell death in breast cancer. J Med Chem 60(24):9990–10012CrossRefPubMed Ouyang L, Zhang L, Liu J, Fu L, Yao D, Zhao Y, Zhang S, Wang G, He G, Liu B (2017) Discovery of a small-molecule bromodomain-containing protein 4 (BRD4) Inhibitor that induces AMP-activated protein kinase-modulated autophagy-associated cell death in breast cancer. J Med Chem 60(24):9990–10012CrossRefPubMed
58.
go back to reference Gosmini R, Nguyen VL, Toum J, Simon C, Brusq JM, Krysa G, Mirguet O, Riou-Eymard AM, Boursier EV, Trottet L, Bamborough P, Clark H, Chung CW, Cutler L, Demont EH, Kaur R, Lewis AJ, Schilling MB, Soden PE, Taylor S, Walker AL, Walker MD, Prinjha RK, Nicodeme E (2014) The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor. J Med Chem 57(19):8111–8131CrossRefPubMed Gosmini R, Nguyen VL, Toum J, Simon C, Brusq JM, Krysa G, Mirguet O, Riou-Eymard AM, Boursier EV, Trottet L, Bamborough P, Clark H, Chung CW, Cutler L, Demont EH, Kaur R, Lewis AJ, Schilling MB, Soden PE, Taylor S, Walker AL, Walker MD, Prinjha RK, Nicodeme E (2014) The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor. J Med Chem 57(19):8111–8131CrossRefPubMed
59.
go back to reference Demont EH, Chung CW, Furze RC, Grandi P, Michon AM, Wellaway C, Barrett N, Bridges AM, Craggs PD, Diallo H, Dixon DP, Douault C, Emmons AJ, Jones EJ, Karamshi BV, Locke K, Mitchell DJ, Mouzon BH, Prinjha RK, Roberts AD, Sheppard RJ, Watson RJ, Bamborough P (2015) Fragment-based discovery of low-micromolar ATAD2 bromodomain inhibitors. J Med Chem 58(14):5649–5673CrossRefPubMed Demont EH, Chung CW, Furze RC, Grandi P, Michon AM, Wellaway C, Barrett N, Bridges AM, Craggs PD, Diallo H, Dixon DP, Douault C, Emmons AJ, Jones EJ, Karamshi BV, Locke K, Mitchell DJ, Mouzon BH, Prinjha RK, Roberts AD, Sheppard RJ, Watson RJ, Bamborough P (2015) Fragment-based discovery of low-micromolar ATAD2 bromodomain inhibitors. J Med Chem 58(14):5649–5673CrossRefPubMed
60.
go back to reference Bamborough P, Chung CW, Furze RC, Grandi P, Michon AM, Sheppard RJ, Barnett H, Diallo H, Dixon DP, Douault C, Jones EJ, Karamshi B, Mitchell DJ, Prinjha RK, Rau C, Watson RJ, Werner T, Demont EH (2015) Structure-based optimization of naphthyridones into potent ATAD2 bromodomain inhibitors. J Med Chem 58(15):6151–6178CrossRefPubMed Bamborough P, Chung CW, Furze RC, Grandi P, Michon AM, Sheppard RJ, Barnett H, Diallo H, Dixon DP, Douault C, Jones EJ, Karamshi B, Mitchell DJ, Prinjha RK, Rau C, Watson RJ, Werner T, Demont EH (2015) Structure-based optimization of naphthyridones into potent ATAD2 bromodomain inhibitors. J Med Chem 58(15):6151–6178CrossRefPubMed
61.
go back to reference B. R, Wang C (US9393232, 2017) Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones B. R, Wang C (US9393232, 2017) Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
62.
go back to reference Ozer HG, El-Gamal D, Powell B, Hing ZA, Blachly JS, Harrington B, Mitchell S, Grieselhuber NR, Williams K, Lai T-H, Alinari L, Baiocchi RA, Brinton L, Baskin E, Cannon M, Beaver L, Goettl VM, Lucas DM, Woyach JA, Sampath D, Lehman AM, Yu L, Zhang J, Ma Y, Zhang Y, Spevak W, Shi S, Severson P, Shellooe R, Carias H, Tsang G, Dong K, Ewing T, Marimuthu A, Tantoy C, Walters J, Sanftner L, Rezaei H, Nespi M, Matusow B, Habets G, Ibrahim P, Zhang C, Mathé EA, Bollag G, Byrd JC, Lapalombella R (2018) BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-1117-0902CrossRefPubMed Ozer HG, El-Gamal D, Powell B, Hing ZA, Blachly JS, Harrington B, Mitchell S, Grieselhuber NR, Williams K, Lai T-H, Alinari L, Baiocchi RA, Brinton L, Baskin E, Cannon M, Beaver L, Goettl VM, Lucas DM, Woyach JA, Sampath D, Lehman AM, Yu L, Zhang J, Ma Y, Zhang Y, Spevak W, Shi S, Severson P, Shellooe R, Carias H, Tsang G, Dong K, Ewing T, Marimuthu A, Tantoy C, Walters J, Sanftner L, Rezaei H, Nespi M, Matusow B, Habets G, Ibrahim P, Zhang C, Mathé EA, Bollag G, Byrd JC, Lapalombella R (2018) BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor. Cancer Discov. https://​doi.​org/​10.​1158/​2159-8290.​CD-1117-0902CrossRefPubMed
63.
go back to reference Gao N, Ren J, Hou L, Zhou Y, Xin L, Wang J, Yu H, Xie Y, Wang H (2016) Identification of novel potent human testis-specific and bromodomain-containing protein (BRDT) inhibitors using crystal structure-based virtual screening. Int J Mol Med 38(1):39–44CrossRefPubMedPubMedCentral Gao N, Ren J, Hou L, Zhou Y, Xin L, Wang J, Yu H, Xie Y, Wang H (2016) Identification of novel potent human testis-specific and bromodomain-containing protein (BRDT) inhibitors using crystal structure-based virtual screening. Int J Mol Med 38(1):39–44CrossRefPubMedPubMedCentral
64.
go back to reference N-n Gao, Hou L, Zhou Y, Xin L, Yang D, Li N, Wang H (2016) Discovery of male anti-fertility inhibitors target BRDT through structure-based virtual screening. Shengzhi Yixue Zazhi 25(6):550–555 N-n Gao, Hou L, Zhou Y, Xin L, Yang D, Li N, Wang H (2016) Discovery of male anti-fertility inhibitors target BRDT through structure-based virtual screening. Shengzhi Yixue Zazhi 25(6):550–555
65.
go back to reference Ayoub AM, Hawk LML, Herzig RJ, Jiang J, Wisniewski AJ, Gee CT, Zhao P, Zhu J-Y, Berndt N, Offei-Addo NK, Scott TG, Qi J, Bradner JE, Ward TR, Schönbrunn E, Georg GI, Pomerantz WCK (2017) BET bromodomain inhibitors with one-step synthesis discovered from virtual screen. J Med Chem 60(12):4805–4817CrossRefPubMedPubMedCentral Ayoub AM, Hawk LML, Herzig RJ, Jiang J, Wisniewski AJ, Gee CT, Zhao P, Zhu J-Y, Berndt N, Offei-Addo NK, Scott TG, Qi J, Bradner JE, Ward TR, Schönbrunn E, Georg GI, Pomerantz WCK (2017) BET bromodomain inhibitors with one-step synthesis discovered from virtual screen. J Med Chem 60(12):4805–4817CrossRefPubMedPubMedCentral
66.
go back to reference Carlino L, Rastelli G (2016) Dual kinase-bromodomain inhibitors in anticancer drug discovery: a structural and pharmacological perspective. J Med Chem 59(20):9305–9320CrossRefPubMed Carlino L, Rastelli G (2016) Dual kinase-bromodomain inhibitors in anticancer drug discovery: a structural and pharmacological perspective. J Med Chem 59(20):9305–9320CrossRefPubMed
67.
go back to reference Devaiah BN, Lewis BA, Cherman N, Hewitt MC, Albrecht BK, Robey PG, Ozato K, Sims RJ, Singer DS (2012) BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA polymerase II carboxy-terminal domain. PNAS 109(18):6927–6932CrossRefPubMed Devaiah BN, Lewis BA, Cherman N, Hewitt MC, Albrecht BK, Robey PG, Ozato K, Sims RJ, Singer DS (2012) BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA polymerase II carboxy-terminal domain. PNAS 109(18):6927–6932CrossRefPubMed
68.
go back to reference Ember SWJ, Zhu J-Y, Olesen SH, Martin MP, Becker A, Berndt N, Georg GI, Schönbrunn E (2014) Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem Biol 9(5):1160–1171CrossRefPubMedPubMedCentral Ember SWJ, Zhu J-Y, Olesen SH, Martin MP, Becker A, Berndt N, Georg GI, Schönbrunn E (2014) Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem Biol 9(5):1160–1171CrossRefPubMedPubMedCentral
69.
go back to reference Ciceri P, Müller S, O’Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C, Martin S, Wodicka LM, Shah NP, Treiber DK, Knapp S (2014) Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol 10(4):305–312CrossRefPubMedPubMedCentral Ciceri P, Müller S, O’Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C, Martin S, Wodicka LM, Shah NP, Treiber DK, Knapp S (2014) Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol 10(4):305–312CrossRefPubMedPubMedCentral
70.
go back to reference Ember SW, Lambert QT, Berndt N, Gunawan S, Ayaz M, Tauro M, Zhu J-Y, Cranfill PJ, Greninger P, Lynch CC, Benes CH, Lawrence HR, Reuther GW, Lawrence NJ, Schönbrunn E (2017) Potent dual BET bromodomain-kinase inhibitors as value-added multitargeted chemical probes and cancer therapeutics. Mol Cancer Ther 16(6):1054–1067CrossRefPubMedPubMedCentral Ember SW, Lambert QT, Berndt N, Gunawan S, Ayaz M, Tauro M, Zhu J-Y, Cranfill PJ, Greninger P, Lynch CC, Benes CH, Lawrence HR, Reuther GW, Lawrence NJ, Schönbrunn E (2017) Potent dual BET bromodomain-kinase inhibitors as value-added multitargeted chemical probes and cancer therapeutics. Mol Cancer Ther 16(6):1054–1067CrossRefPubMedPubMedCentral
71.
go back to reference Waring MJ, Chen H, Rabow AA, Walker G, Bobby R (2016) Potent and selective bivalent inhibitors of BET bromodomains. Nat Chem Biol 12(12):1097–1104CrossRefPubMed Waring MJ, Chen H, Rabow AA, Walker G, Bobby R (2016) Potent and selective bivalent inhibitors of BET bromodomains. Nat Chem Biol 12(12):1097–1104CrossRefPubMed
72.
go back to reference Lu J, Qian Y, Altieri M, Dong H, Wang J, Raina K, Hines J, Winkler JD, Crew AP, Coleman K, Crews CM (2015) Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem Biol 22(6):755–763CrossRefPubMedPubMedCentral Lu J, Qian Y, Altieri M, Dong H, Wang J, Raina K, Hines J, Winkler JD, Crew AP, Coleman K, Crews CM (2015) Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem Biol 22(6):755–763CrossRefPubMedPubMedCentral
73.
go back to reference Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, Bradner JE (2015) Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348(6241):1376–1381CrossRefPubMedPubMedCentral Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, Bradner JE (2015) Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348(6241):1376–1381CrossRefPubMedPubMedCentral
74.
go back to reference Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E, Lin M, Liu L, Yang C-Y, Zhao Y, McEachern D, Przybranowski S, Wen B, Sun D, Wang S (2017) Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J Med Chem 61(2):462–481CrossRefPubMedPubMedCentral Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E, Lin M, Liu L, Yang C-Y, Zhao Y, McEachern D, Przybranowski S, Wen B, Sun D, Wang S (2017) Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J Med Chem 61(2):462–481CrossRefPubMedPubMedCentral
76.
go back to reference Kharenko OA, Hansen HC (2017) Novel approaches to targeting BRD4. Drug Discov Today Technol 24:19–24CrossRefPubMed Kharenko OA, Hansen HC (2017) Novel approaches to targeting BRD4. Drug Discov Today Technol 24:19–24CrossRefPubMed
77.
go back to reference Churcher I (2017) PROTAC-induced protein degradations in drug discovery: breaking the rules or just making new ones? J Med Chem 61(2):444–452CrossRefPubMed Churcher I (2017) PROTAC-induced protein degradations in drug discovery: breaking the rules or just making new ones? J Med Chem 61(2):444–452CrossRefPubMed
78.
go back to reference Gadd MS, Testa A, Lucas X, Chan K-H, Chen W, Lamont DJ, Zengerle M, Ciulli A (2017) Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol 13:514CrossRefPubMedPubMedCentral Gadd MS, Testa A, Lucas X, Chan K-H, Chen W, Lamont DJ, Zengerle M, Ciulli A (2017) Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol 13:514CrossRefPubMedPubMedCentral
79.
go back to reference Crawford TD, Tsui V, Flynn EM, Wang S, Taylor AM, Côté A, Audia JE, Beresini MH, Burdick DJ, Cummings R, Dakin LA, Duplessis M, Good AC, Hewitt MC, Huang H-R, Jayaram H, Kiefer JR, Jiang Y, Murray J, Nasveschuk CG, Pardo E, Poy F, Romero FA, Tang Y, Wang J, Xu Z, Zawadzke LE, Zhu X, Albrecht BK, Magnuson SR, Bellon S, Cochran AG (2016) Diving into the water: Inducible binding conformations for BRD4, TAF1(2), BRD9, and CECR2 bromodomains. J Med Chem 59(11):5391–5402CrossRefPubMed Crawford TD, Tsui V, Flynn EM, Wang S, Taylor AM, Côté A, Audia JE, Beresini MH, Burdick DJ, Cummings R, Dakin LA, Duplessis M, Good AC, Hewitt MC, Huang H-R, Jayaram H, Kiefer JR, Jiang Y, Murray J, Nasveschuk CG, Pardo E, Poy F, Romero FA, Tang Y, Wang J, Xu Z, Zawadzke LE, Zhu X, Albrecht BK, Magnuson SR, Bellon S, Cochran AG (2016) Diving into the water: Inducible binding conformations for BRD4, TAF1(2), BRD9, and CECR2 bromodomains. J Med Chem 59(11):5391–5402CrossRefPubMed
80.
go back to reference Wu P, Clausen MH, Nielsen TE (2015) Allosteric small-molecule kinase inhibitors. Pharmacol Ther 156:59–68CrossRefPubMed Wu P, Clausen MH, Nielsen TE (2015) Allosteric small-molecule kinase inhibitors. Pharmacol Ther 156:59–68CrossRefPubMed
Metadata
Title
BRDT Inhibitors for Male Contraceptive Drug Discovery: Current Status
Authors
Zhenyuan Miao
Xianghong Guan
Jiewei Jiang
Gunda I. Georg
Copyright Year
2018
Publisher
Springer Singapore
DOI
https://doi.org/10.1007/978-981-13-0773-7_11